financetom
Business
financetom
/
Business
/
enCore Energy Clears Key U.S. Federal Hurdle for Dewey Burdock Uranium Project After EPA Board Denies Petition
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
enCore Energy Clears Key U.S. Federal Hurdle for Dewey Burdock Uranium Project After EPA Board Denies Petition
Sep 16, 2025 5:23 AM

07:45 AM EDT, 09/16/2025 (MT Newswires) -- enCore Energy (EU.V) said Tuesday that the U.S. Environmental Protection Agency's Environmental Appeals Board allowed the Dewey Burdock in-situ recovery uranium project in South Dakota to advance through federal permitting after denying a petition to block the development.

The petition was filed by the Oglala Sioux Tribe, Black Hills Clean Water Alliance and NDN Collective in an attempt to prevent the EPA from issuing Class III and Class V underground injection control permits for the project.

With the EAB's ruling, enCore said all major federal authorizations for the project, including the NRC source materials license and EPA UIC permits, are final and effective.

"This decision by the EAB affirms the validity of the permits and the integrity of the regulatory process following years of administrative and judicial review," enCore's acting chief executive officer Robert Willette said.

enCore said it plans to commence state permitting activities in 2025, accelerating the project toward development ahead of schedule. Dewey Burdock Project was approved for fast-track federal permitting under the Fast-41 Program on Aug. 28.

enCore's share price jumped 11.9% Monday to $3.48 on the TSXV.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Copyright 2023-2026 - www.financetom.com All Rights Reserved